+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Canavan Disease R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749241
  • Report
  • February 2019
  • Region: Global
  • 25 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

The global demand for Canavan Disease treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Canavan Disease pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Canavan Disease pipeline companies from advancing their products into Phase 3 or Phase 4.

Canavan Disease Report Description

The 2019 pipeline study on Canavan Disease pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Canavan Disease pipeline compounds.

The Canavan Disease pipeline guide presents information on all active drugs currently being developed for Canavan Disease. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Canavan Disease pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Canavan Disease drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Canavan Disease product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Canavan Disease pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Canavan Disease pipeline report includes
  • An overview of Canavan Disease disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Canavan Disease pipeline
  • Company wise list of Canavan Disease pipeline
  • Mechanism of Action wise Canavan Disease pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Canavan Disease pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Canavan Disease pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Canavan Disease pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

1.1 List of Tables
1.2 List of Figures

2. Global Canavan Disease Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Canavan Disease Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Canavan Disease pipeline, H1- 2019
3.5 Mechanism of Action wise Canavan Disease Pipeline Candidates

4 Orphan Star Therapeutics, LLC Canavan Disease Pipeline Details
4.1 Orphan Star Therapeutics, LLC Business Profile
4.2 Orphan Star Therapeutics, LLC Canavan Disease Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Pfizer Inc Canavan Disease Pipeline Details
5.1 Pfizer Inc Business Profile
5.2 Pfizer Inc Canavan Disease Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. Latest Canavan Disease Drug Pipeline Developments, 2019

7. Appendix
7.1 About Us
7.2 Sources and Methodology
7.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Orphan Star Therapeutics, LLC
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll